Table of Contents
EXECUTIVE SUMMARY
- Datamonitor insight into the antidepressants market
- Related reports
- Upcoming related reports
MARKET DEFINITION
- Market definition for this report
MARKET OVERVIEW
- Seven major markets
- Current and future market overview
- Opportunities and threats
- US
- Current and future market assessment
- Opportunities and threats
- Japan
- Current and future market assessment
- Opportunities and threats
- Five major European markets (5EU)
- Current and future market assessment
- Opportunities and threats
- France
- Current and future market assessment
- Germany
- Current and future market assessment
- Italy
- Current and future market assessment
- Spain
- Current and future market assessment
- UK
- Current and future market assessment
- Global and rest of the world snapshot
- Current market assessment
BRAND DYNAMICS
- Overview of competitive landscape
- Drivers of brand choice
- Established efficacy - essential in non-depression conditions
- Side effect profile - no class is perfect
- Presence of comorbid disorders - both medical and psychiatric
- Prior treatment history - positive or negative response
- Cost - generic availablility hinders brand prescribing
- US formulary tier status for leading brands
- Availability of generics negatively impacts brand tier status
- Trends in marketing strategies
- Brand website
- Promotional spend
- Direct-to-consumer advertising
- Effexor IR & XR (venlafaxine; Wyeth)
- Drug overview
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Lexapro (escitalopram; Lundbeck and Forest)
- Drug overview
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Cymbalta (duloxetine; Eli Lilly and Boehringer Ingelheim)
- Drug overview
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Pristiq (desvenlafaxine; Wyeth)
- Drug overview
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Valdoxan/ Thymanax (agomelatine; Novartis & Servier)
- Drug overview
- Drug profile
- Development overview
- Product positioning
- Drug forecast to 2018
- Vilazodone (Clinical Data Inc)
- Drug overview
- Drug profile
- Development overview
- Product positioning
- Drug forecast to 2018
- Lu AA21004 (Lundbeck & Takeda)
- Drug overview
- Drug profile
- Development overview
- Product positioning
KEY DEVELOPERS
- Strategic overview
- Leading companies in the branded antidepressant class market
- Trends in corporate strategy
- Regional focus of leading companies
- Recent strategic partnerships/deals
- Licensing deals remain an important strategy for major players in the
antidepressant market
- Wyeth
- Corporate strategy
- Antidepressant class market portfolio assessment
- Lundbeck
- Corporate strategy
- Antidepressant class market portfolio assessment
- Forest
- Corporate strategy
- Antidepressant class market portfolio assessment
CASE STUDIES
- Introduction
- Indication expansion strategies
- Anxiety disorders have proven to be a very profitable target
- Pain indications - SNRIs prove more effective than the SSRIs
- Urology and women' s health - unsuccessful expansion strategies thus far
- Insomnia associated with depression
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
- Other
APPENDIX A - MARKET ASSUMPTIONS
- New product launches
- Patent expiry dates
- Data definitions, limitations and assumptions
- Standard units
- Country group definitions
- Derivation of sales forecasts and pricing trends
APPENDIX B
- Contributing experts
- Conferences attended
- Report methodology
TABLES
- Table: Sales and growth of antidepressant drug classes in the seven major
markets, 2005-2018
- Table: Key events impacting the antidepressant market, 2009 - 18
- Table: Seven major market antidepressant drug class sales forecast ($m),
2008 - 2018
- Table: Summary of opportunities and threats in the antidepressant class
market across the seven major markets, 2009
- Table: Sales and growth of antidepressant drug classes in the US, 2005 -
2018
- Table: US antidepressant drug class market sales forecast ($m), 2008 - 2018
- Table: Summary of opportunities and threats in antidepressant class market
in the US, 2009
- Table: Sales and growth of antidepressant drug classes in Japan, 2005 -
2018
- Table: Japanese antidepressant drug class market sales forecast ($m), 2008
- 2018
- Table: Summary of opportunities and threats in the antidepressant class
market in Japan, 2009
- Table: Sales and growth of antidepressant drug classes in the 5EU, 2005 -
2018
- Table: 5EU antidepressant drug class market sales forecast ($m), 2008 -
2018
- Table: Summary of opportunities and threats in the antidepressant class
market in the five major European market, 2009
- Table: Sales and growth of antidepressant drug classes in France, 2005 -
2018
- Table: Sales and growth of antidepressant drug classes in Germany, 2005 -
2018
- Table: Sales and growth of antidepressant drug classes in Italy, 2005 -
2018
- Table: Sales and growth of antidepressant drug classes in Spain, 2005 -
2018
- Table: Sales and growth of antidepressant drug classes in the UK, 2005 -
2018
- Table: Global sales ($m) dynamics of the antidepressant class market, 2004
- 08
- Table: Comparison of leading antidepressant brand sales ($m) in the seven
major markets and the rest of the world (ROW), 2004 - 08
- Table: Leading branded antidepressant drug sales in the seven major
markets ($m), 2008 - 2018
- Table: Key late-stage pipeline antidepressants , 2009
- Table: Representative formulary tier status in the US for leading
antidepressant brands, 2009
- Table: Effexor/ Effexor XR - drug profile, 2009
- Table: Impacting factors on the revenues of Effexor XR, 2009 - 2018
- Table: Lexapro - drug profile, 2009
- Table: Impacting factors on the revenues of Lexapro, 2009 - 2018
- Table: Cymbalta - drug profile, 2009
- Table: Impacting factors on the revenues of Cymbalta, 2009 - 2018
- Table: Pristiq - drug profile, 2009
- Table: Impacting factors on the revenues of Pristiq, 2009 - 2018
- Table: Valdoxan - drug profile, 2009
- Table: US clinical trial summary for Valdoxan (agomelatine)
- Table: Impacting factors on the revenues of Valdoxan, 2009 - 2018
- Table: Vilazodone - drug profile, 2009
- Table: Phase III clinical trial summary for vilazodone
- Table: Impacting factors on the revenues of vilazodone, 2009 - 2018
- Table: Lu AA21004 - drug profile, 2009
- Table: Completed Phase III trials of Lu AA21004 in GAD, 2009
- Table: Leading companies in the branded seven major market antidepressant
market by sales value, 2004 - 08
- Table: Key strategic deals and events in the antidepressant market, 2009
- Table: Lundbeck' s antidepressant development pipeline, 2009
- Table: Datamonitor' s estimated launch dates for key late-stage pipeline
antidepressants in the seven major markets, 2009 - 2018
- Table: Patent expiry dates for the key antidepressant brands in the seven
major markets, 2009 - 2018
FIGURES
- Figure: Change in seven major market antidepressant class sales value ($)
by class, 2005 - 08
- Figure: Change in seven major market antidepressant class sales value ($)
by country, 2005 - 08
- Figure: Antidepressant market sales ($) by drug class in the seven major
markets, 2008 - 2018
- Figure: Forecast growth dynamics of the seven major market antidepressant
sub-classes, 2008 - 2018
- Figure: Change in US market antidepressant class sales value ($) by class,
2005 - 08
- Figure: US antidepressant market sales forecast by class, 2008 - 2018
- Figure: Ex-manufacture price point ($) of three leading antidepressant
brands in the US and 5EU, 2008
- Figure: Rate of sales volume (IMS standard units sold) generic erosion for
Zoloft (sertraline; Pfizer) following regional patent expiries
- Figure: Change in Japanese market antidepressant class sales value ($) by
class, 2005 - 08
- Figure: Japanese antidepressant market sales forecast by class, 2008 - 2018
- Figure: Brand and generic antidepressant class sale volume across the
seven major markets, 2008
- Figure: Change in 5EU market antidepressant class sales value ($) by
class, 2005 - 08
- Figure: Sales value ($) dynamics of the 5EU antidepressant class markets,
2005 - 08
- Figure: 5EU antidepressant market sales forecast by class, 2008 - 2018
- Figure: Percentage of total antidepressant class IMS standard units sold
attributed to the SSRI and SNRI classes in each of the seven major markets,
2008
- Figure: Ex-manufacturer price point ($) of three leading antidepressant
brands in the five major EU countries, 2008
- Figure: Brand and generic antidepressant class sales volume across the
five major EU countries, 2008
- Figure: Change antidepressant market class sales value ($) in France, 2005
- 08
- Figure: Antidepressant market sales forecast in France by class, 2008 - 18
- Figure: Change antidepressant market class sales value ($) in Germany,
2005 - 08
- Figure: Antidepressant market sales forecast in Germany by class, 2008 - 18
- Figure: Change antidepressant market class sales value ($) in Italy, 2005
- 08
- Figure: Antidepressant market sales forecast in Italy by class, 2008 - 18
- Figure: Change antidepressant market class sales value ($) in Spain, 2005
- 08
- Figure: Antidepressant market sales forecast in Spain by class, 2008 - 18
- Figure: Change antidepressant market class sales value ($) in the UK, 2005
- 08
- Figure: Antidepressant market sales forecast in the UK by class, 2008 - 18
- Figure: Change in global antidepressant market sales value ($) by region,
2004 - 08
- Figure: Global antidepressant class market sales ($m) dynamics by major
region, 2004 - 08
- Figure: Change in global antidepressant market sales volume by region,
2004 - 08
- Figure: Global antidepressant class market sales volume (IMS standard
units sold) and sales value ($) by region, 2008
- Figure: Rest of the world antidepressant class regional market dynamics,
2004 - 08
- Figure: Key d rivers of antidepressant brand choice, 2009
- Figure: Non-direct to consumer promotional spend for key antidepressant
brands in the US and 5EU, Q2 2007 to Q2 2008
- Figure: Effexor XR (venlafaxine extended release; Wyeth) sales volume by
condition in the US and 5EU, 2008
- Figure: Effexor/Effexor XR SWOT analysis, 2009
- Figure: Effexor XR sales forecast ($m) by country in the seven major
markets, 2008 - 2018
- Figure: Lexapro (escitalopram, Lundbeck & Forest) sales volume by
condition in the US and 5EU, 2008
- Figure: Lexapro SWOT analysis, 2009
- Figure: Lexapro sales forecast ($m) by country in the seven major markets,
2008 - 2018
- Figure: Cymbalta (duloxetine; Eli Lilly and Boehringer Ingelheim) sales
volume by condition in the US and five major European pharmaceutical market
countries, 2008
- Figure: Cymbalta SWOT analysis, 2009
- Figure: Cymbalta sales ($m) dynamics by indication in the seven major
markets, 2008 - 2012
- Figure: Cymbalta sales forecast ($m) by country in the seven major
markets, 2008 - 2018
- Figure: Pristiq SWOT analysis, 2009
- Figure: Pristiq sales forecast ($m) in the US and Japan, 2008 - 2018
- Figure: Valdoxan sales forecast ($m) by country in the seven major
markets, 2009 - 2018
- Figure: Vilazodone sales forecast ($m) in the US, 2009 - 2018
- Figure: Sales value dynamics of the top 10 branded antidepressant class
market companies by seven major market revenues ($m), 2004 - 08
- Figure: Regional focus of the leading 10 companies in the branded
antidepressant market across the seven major markets by antidepressant sales
value, 2008
- Figure: Combined seven major market sales forecast for Wyeth' s Effexor XR
and Pristiq, 2008 - 2018
- Figure: Comparative sales volume (IMS standard units) of Lexapro
(escitalopram), Celexa (citalopram) and generic citalopram in the US and five
major EU countries, 2008
- Figure: Forest' s antidepressant class franchise forecast, 2008 - 09
- Figure: Specific anxiety disorder indications for the leading
antidepressant brands in the US, 5EU and Japan, 2009
- Figure: Proportion of seven major market sales value generated from
anxiety disorders for the three leading antidepressant class brands, 2008
|
Related Report
|
View Cart
